Literature DB >> 23040751

Medical versus surgical management of prolactinomas.

Michael C Oh1, Sandeep Kunwar, Lewis Blevins, Manish K Aghi.   

Abstract

Prolactinomas are the most common hormone-secreting pituitary adenomas, comprising 40% of all pituitary tumors. Prolactinomas present a unique challenge for clinicians, as these tumors are amenable to either medical or surgical treatments based on patients' comorbidities, tolerance to medical treatment, and the response of tumors to medical treatment. Rare prolactinomas that are unresponsive to either medical or surgical treatment modalities may be responsive to radiation therapy. This article reviews the recent advancements in the management of prolactinomas.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23040751     DOI: 10.1016/j.nec.2012.06.010

Source DB:  PubMed          Journal:  Neurosurg Clin N Am        ISSN: 1042-3680            Impact factor:   2.509


  4 in total

1.  Gamma Knife radiosurgery for medically and surgically refractory prolactinomas: long-term results.

Authors:  Or Cohen-Inbar; Zhiyuan Xu; David Schlesinger; Mary Lee Vance; Jason P Sheehan
Journal:  Pituitary       Date:  2015-12       Impact factor: 4.107

2.  Cost-Effectiveness Analysis of Surgical versus Medical Treatment of Prolactinomas.

Authors:  Corinna C Zygourakis; Brandon S Imber; Rebecca Chen; Seunggu J Han; Lewis Blevins; Annette Molinaro; James G Kahn; Manish K Aghi
Journal:  J Neurol Surg B Skull Base       Date:  2016-09-27

3.  The Chance of Permanent Cure for Micro- and Macroprolactinomas, Medication or Surgery? A Systematic Review and Meta-Analysis.

Authors:  Qianquan Ma; Jun Su; Ying Li; Jiaxing Wang; Wenyong Long; Mei Luo; Qing Liu
Journal:  Front Endocrinol (Lausanne)       Date:  2018-10-25       Impact factor: 5.555

4.  Early prediction of long-term response to cabergoline in patients with macroprolactinomas.

Authors:  Youngki Lee; Cheol Ryong Ku; Eui-Hyun Kim; Jae Won Hong; Eun Jig Lee; Sun Ho Kim
Journal:  Endocrinol Metab (Seoul)       Date:  2014-09-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.